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Introduction
Chemotherapy for diﬀerent types of cancer is often life-saving.
However, the spectrum of side eﬀects may involve the central nervous
system (CNS) and lead to severe emotional and cognitive disturbances,
a syndrome often referred to as “chemobrain”. It is reported to occur
with various degrees of severity in about two thirds of patients
following chemotherapy [1,14,2,9]. At present, the mechanisms and
determining factors of this syndrome are not well understood.
Case presentation
A 43-year-old female Caucasian patient was referred to our clinic as
she had complained of frequent mood swings, found it diﬃcult to
concentrate and to remember what she had been told or read shortly
before. Remarkably, in one instance she had left her electric iron
switched on for several days and in another she had put a burning
candle into a drawer and closed it afterwards.
Her medical history revealed that four years earlier breast cancer of
the right breast had been diagnosed, and the patient had been tested
positive for BRCA1 oncogen. At that time she had become a patient of a
nearby Comprehensive Cancer Center (CCCU) and underwent breast-
conserving therapy starting with systemic chemotherapy according to
the GeparQuinto protocol (4xEpirubicin/Cyclophosphamide and
4xDocetaxel/Trastuzumab, 2×4 cycles; Trastuzumab for 1 year),
additionally Goserelin. Six months after starting chemotherapy a
breast-conserving operation was performed including axillary lympho-
nodectomy. Tumor staging was as follows: ypT2, ypN1a (1/23), M0, L1,
V0, R0, G3, ER0, PgR0, HER-2 status 3+. Surgery was followed by
radiation therapy of the breast including the infra- and supraclavicular
draining lymphatic systems applying a total dose of 66,4 Gy. At that
time the patient found out that her mother and sister had also suﬀered
from BRCA1-positive mammary carcinoma. She reported no mental
health problems prior to her cancer diagnosis.
Convalescence of the patient proved to be protracted, and she
continued complaining of concentration and memory problems accom-
panied by mood swings and rumination. Four years after initial
diagnosis she was admitted to our psychiatric inpatient department.
She had been unable to work in her former profession as a manager of a
car rental company due to her cognitive deﬁcits. In addition, the long-
lasting relationship with her boyfriend and business partner had ended.
However, she had been able to begin a new relationship with a very
empathic and supportive young man.
On admission, she was alert, fully oriented, but logorrheic, some-
what agitated, and showed depressed mood (Beck Depression
Inventory, BDI, 48). There were no psychotic symptoms, and the
patient denied having suicidal intents, but admitted having had suicidal
thoughts previously.
On clinical examination, somatic including neurological ﬁndings
were unremarkable, except for a slight, postoperative breast asymmetry
(right< left).
On clinical grounds, the following diﬀerential diagnoses were
considered: 1. Major Depression, 2. Bipolar II Disorder, 3. Epilepsy, 4.
Frontotemporal Dementia, 5. HIV Encephalopathy, 6. Chemobrain.
Routine blood tests, HIV testing, ECG, routine and long-term EEG
were all normal. CSF analysis: Total protein, albumin, IgG within
normal ranges. Reiber diagram: No disturbances of the blood-brain-
barrier (BBB), no intrathecal IgG synthesis; NMDA receptor antibodies
negative, τ-protein and β-amyloid(1–42) within normal ranges.
Cranial MRI (cMRI) including gadolinium enhancement was per-
formed twice in this patient with a time interval of 28 months. The
second examination (Fig. 1a,b) took place in our clinic and showed
moderate brain atrophy with fronto-temporal accentuation (Fig. 1a). As
a supplementary ﬁnding, an arachnoid cyst was detected at the left
temporal pole (Fig. 1b). No metastases were found. In the earlier cMRI
performed in a private radiology practice, slightly accentuated perivas-
cular spaces, but no noticeable brain atrophy had been described. An
arachnoid cyst (type I) of identical size and location had already been
visible. Gadolinium enhancement had not been indicative of any further
pathology.
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Extensive neuropsychological testing included components of the
Wechsler Adult Intelligence Scale (WAIS), the Ray Auditory Verbal
Learning Test (RAVLT), the Multiple Choice Vocabulary
(“Mehrfachwahl-Wortschatztest”, MWT), the Regensburg Word
Fluency Test (“Regensburger Wortﬂüssigkeitstest”, RWT), and the
Test Battery for the Assessment of Attention (“Testbatterie zur
Aufmerksamkeitsprüfung”, TAP). Table 1 provides a short overview
of the test results which reveal distinct impairment of several cognitive
functions. Remarkably, the more verbally oriented tests which are
known to be relatively resistant against organic brain damage showed
normal results. Also, the MWT, which allows an estimation of the
premorbid intelligence level, gave a result in the average range.
Considering the available data, we concluded that the most prob-
able diagnosis in this patient was “chemobrain”. In the absence of
evidence-based treatment recommendations for this syndrome, the
patient received antidepressive combination treatment with venlafaxin
(112,5 mg/d) and mirtazapin (15 mg/d), supplemented by lithium
carbonate (675 mg/d) and - because of her agitation and thought
disorder (rumination) - neuroleptic treatment with aripiprazol (5 mg/d)
and quetiapin (150 mg/d) under therapeutic drug monitoring (TDM).
As an additional therapeutic measure, cognitive behavioral psychother-
apy (CBT) was initiated. At discharge, the patient’s depressive symp-
toms had somewhat improved (BDI 36), but her status was otherwise
unchanged. She has been lost to follow-up.
Discussion and conclusions
This case raises a number of issues, e.g. what are the causative and
determining factors of chemobrain with regard to type of chemother-
apy, dosage and combination treatments, such as cytostatic plus
immunomodulatory agents? What are the respective roles and possible
interactions of chemotherapy and radiotherapy in the pathogenesis of
this syndrome? Experimental as well as clinical studies indicate that
Fig. 1. a: cMRI, coronal section, T1 weighted, showing enlarged outer CSF spaces with
fronto-temporal accentuation and normal width of the ventricles (Courtesy by Dr. Hinrich
Prüß, Radiology Ravensburg). b: cMRI, horizontal section, T2 weighted, showing an
arachnoid cyst at the left temporal pole (Courtesy by Dr. Hinrich Prüß, Radiology
Ravensburg).
Table 1
Neuropsychological test results of the patient (for abbreviations see text; wherever
possible, results are presented as x ̅±S.D.).
Tests performed Results
MWT IQ between 91 and 109,
raw value: 21 points
(average range: 85–115 points)
RAVLT total learning: percent
rank (PR): 75; T value: 56
delayed recall: PR 50–65;
T: 50–53
loss after delay: PR 45–65;
T: 48–54
corrected recognition:
T: 53
(average range)
WAIS subtests:
a) Number
reproduction
9 points (within normal range)
b) Matrix test 6 points (distinctly below average)
RWT subtests:
a) Lexical category:
words beginning
with K
PR 3%
b) Lexical category:
words beginning
with G-R
PR 2%
c) Semantic category:
food
PR 8%
d) Semantic category:
clothing - ﬂower
PR 2%
(all subtests far below average)
TAP subtests:
a) Alertness reaction time to visual stimulus without acoustic signal:
x ̅ = 642 (T=21)±162 (T=27) ms
reaction time to visual stimulus with acoustic signal: x ̅ =
659 (T< 20)± 184 (T=24) ms (both far below average)
b) Flexibility mean reaction time: 997 ms; T< 20 (far below average)
c) Go/No go 1 mistake (T=52)
(average)
mean reaction time: 558 ms; T=31
(far below average)
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CNS progenitor cells, neurogenesis, and oligodendrocytes are targets of
chemotherapeutic agents [3], and that the resulting damage may be
involved in the pathogenesis of chemobrain [4]. In a review of 53
studies, Wefel and Schagen [14] were able to identify a number of risk
factors for chemotherapy-associated cognitive disturbances. The most
prominent of them were: High total dose of chemotherapeutic agent,
combinations of diﬀerent substances, intraarterial or intrathecal appli-
cation, additional radiation or hormonal therapy. The extent of loss of
cognitive ability appears to depend, at least in part, on “cognitive
reserve”, which in turn is dependent on age and educational level of the
patient [10]. Interestingly, cognitive factors have been demonstrated to
be associated with treatment adherence [11].
The fact that psychiatric examination and neuropsychological
testing had not been performed before starting chemotherapy (and
radiotherapy) in our patient constitutes a clear limitation of this case
study.
With regard to therapeutic options, there is as yet no approved
psychopharmacological treatment for chemobrain in Germany.
Nevertheless, a number of substances have been investigated in this
respect, and there is some evidence that oﬀ-label use of antidepressants
and lithium (among others) may be helpful [2]. In addition, CBT has
been shown to be superior to a control condition [7].
Another important question emerges from the follow-up cMRI
ﬁndings in our patient. In the second cMRI, fronto-temporally accen-
tuated brain atrophy was described, but no such ﬁnding had been
visible in the ﬁrst cMRI. Therefore, it could be asked, if progressive
brain atrophy might be a constituent of the chemobrain syndrome in
this case. Our observations support the notion that the use of more
aggressive and combined treatment modalities in cancer therapy may
cause delayed neuropsychiatric complications, such as cognitive de-
cline, progressive myelin disruption, and brain atrophy [12,13,5,8].
Taking into account the high incidence of chemobrain (about two
thirds of patients according to [9]) and its potentially deleterious
impact on quality of life [2], it appears to be an important ethical issue
whether information on the risk of developing this syndrome should be
included in the informed consent obtained before starting these
invasive treatments.
In terms of prevention, personalized chemotherapy for breast cancer
and possibly other types of cancer should be envisaged as a long-term
goal, regarding not only response behavior, but also tolerability, as has
recently been suggested for radiation therapy [6].
Consent
Written informed consent was obtained from the patient for
publication of this case report and accompanying images. A copy of
the written consent is available for review by the Editor-in-Chief of this
journal on request.
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